Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.

Journal article

Rajakumaraswamy N. et al, (2023), Clin Lymphoma Myeloma Leuk

Changing treatment changing prognosis of mutations

Journal article

Vyas P., (2023), Blood, 142, 1583 - 1585

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.

Journal article

Lachowiez CA. et al, (2023), Blood Cancer Discov, 4, 276 - 293

An Overview of Targeted Therapies in Acute Myeloid Leukemia.

Journal article

Turkalj S. et al, (2023), Hemasphere, 7

Load More